Professor Udai Banerji, Group Leader
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
Clinical Cancer Research (Nov 2022). Banerjee S, Michalarea V, Ang JE, Ingles Garces A, Biondo A, Ruddle R, Raynaud F, Riisnaes R, Gurel B, Tunariu N, Prout T, Parmar M, Zachariou A, Turner A, Jenkins B, Minchom A, Lopez J, de Bono J, Hall E, Banerji U.
Dr Anna Kirby, Consultant Clinical Oncologist
Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial
The Lancet (Jun 2023). Haviland JS, Kirby AM, Griffin CL, Sydenham MA, Titley JC, Emson M, Hopwood P, Yarnold JR, Bliss JM.
Dr Matthew Jessop, Postdoctoral Training Fellow
Structural basis of tankyrase activation by polymerization
Nature (Nov 2022). Pillay N, Mariotti L, Zaleska M, Inian O, Jessop M, Hibbs S, Hopkins PCR, Templeton CM, Beuron F, Morris EP, Guettler S.
Dr Anguraj Sadanandam, Group Leader
Uridine-derived ribose fuels glucose-restricted pancreatic cancer
Nature (May 2023). Poudel P, Regulan C, Ps H, Nyamundanda G, Sadanandam A.